

# UbiVac Appoints Walter J. Urba, M.D., Ph.D., to Scientific Advisory Board

*Former Providence Cancer Institute CMO and cancer immunotherapy pioneer Dr. Walter Urba joins UbiVac SAB to advance Dark Matter immunotherapies.*



World's 1st "Dark Matter" cancer vaccine shows promise as it tripled response rate and doubled overall survival in early phase combination immunotherapy clinical trial.

PORTLAND, OR, UNITED STATES, May 18, 2026 /EINPresswire.com/ -- [UbiVac, a clinical-stage immunotherapy and cancer target discovery company](#)

developing off-the-shelf cancer immunotherapies targeting [Dark](#)

[Genome-derived "Dark Matter" antigens](#), today announced the appointment of Walter J. Urba to its Scientific Advisory Board.

Dr. Urba is an internationally recognized leader in cancer immunotherapy and translational oncology. He previously served as Chief Medical Officer of Providence Cancer Institute and Founding Director of the Cancer Research Program at the Earle A. Chiles Research Institute, where he helped establish one of the nation's leading immuno-oncology research and clinical trial programs. Dr. Urba has played a major role in advancing cytokine therapy, cancer vaccines, adoptive cellular therapy, and immune checkpoint inhibition.

“

I am excited to join UbiVac's Scientific Advisory Board at a time when the field is increasingly recognizing the importance of non-canonical tumor antigens as targets for immunotherapy”

*Walter J. Urba, M.D., Ph.D.,  
Member, UbiVac's Scientific  
Advisory Board*

“Dr. Urba has been deeply involved in the scientific strategy behind UbiVac since the earliest development of our vaccine platform and was the principal investigator on the first two NCI-funded clinical trials evaluating our

technology,” said Bernard A. Fox, Founder and CEO of UbiVac. “His leadership in cancer immunotherapy and translational medicine has helped shape the field, and we are honored to formally welcome him to UbiVac's Scientific Advisory Board as we advance our Dark Matter immunotherapy platform into later-stage development.”

UbiVac's lead product candidate, DPV-001, is an off-the-shelf microvesicle-based immunotherapy

designed to induce broad anti-tumor immune responses against shared tumor-associated antigens, including Dark Genome-derived “Dark Matter” antigens. In a Phase Ib combination immunotherapy study in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), DPV-001 combination immunotherapy more than doubled overall survival compared with historical outcomes reported for standard-of-care pembrolizumab.

“I am excited to join UbiVac’s Scientific Advisory Board at a time when the field is increasingly recognizing the importance of non-canonical tumor antigens as targets for immunotherapy,” said Dr. Urba. “UbiVac’s platform is uniquely positioned to exploit this emerging biology by combining broad antigenic coverage with endogenous immune stimulation in an off-the-shelf therapeutic approach.”

UbiVac is advancing its Dark Matter immunotherapy platform across multiple solid tumor indications and leveraging immune responses generated against hundreds of Dark Genome-derived antigens to identify novel targets for future immunotherapeutic strategies, including T cell engagers and antibody-drug conjugates.

#### About UbiVac

UbiVac is a clinical-stage immunotherapy and cancer target discovery company developing off-the-shelf cancer immunotherapies targeting cancer’s “Dark Matter” — non-canonical, non-mutated shared tumor antigens derived from the Dark Genome. UbiVac’s lead product candidate, DPV-001, is designed to induce broad T cell, B cell, and innate immune responses against hundreds of tumor-associated antigens expressed across a broad spectrum of solid tumors, including cancers of the prostate, breast, head and neck, pancreas, lung, ovary, brain, kidney, bladder, and colon. UbiVac is leveraging immune responses against these shared antigens to develop next-generation immunotherapies and novel targets for T cell engagers and antibody-drug conjugates.

Bernard A. Fox, PhD

UbiVac

+1 971-413-7139

press@ubivac.com

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/913254037>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.